Group A Beta Hemolytic Streptococci (GAS) is the most critical human pathogen that leads to tonsillopharyngitis. The aims of this study were to identify GAS isolates and to determine emm typing, the coverage rate of available vaccines, and the distribution of superantigen gene profiles. 15 GAS isolates were isolated from throat cultures of 200 patients with tonsillopharyngitis, who were admitted to Canakkale Health Application and Research Hospital between October 2017 and May 2018. Identification of the isolates was performed by conventional methods and 16S rRNA sequence analysis. emm typing and exotoxin profiling of the isolates were performed by polymerase chain reaction. 7.5% GAS was detected in 200 patients. All the GAS isolates were identified as S. pyogenes. emm typing can be carried out in 13 S. pyogenes isolates. emm89 (33.3%), emm44 (20%), emm6 (13.3%), emm84 (6.7%), emm1 (6.7%), and emm18.1 (6.7%) were found to be six emm types. The coverage rate of S. pyogenes strains for 26-valent vaccine was 61.5% and for the 30-valent vaccine 84.6%. The most common exotoxin was speB (86.7%), followed by speC (60%), speF (33.3%), ssa (26.7%), speA (20%), speM (20%), speJ (13.3%), speL (6.7%), and speI (6.7%). As a result of determining the emm types of S. pyogenes species in Canakkale, it was concluded that the potential of 30-valent vaccine should be considered in Turkey and development of vaccines containing exotoxin types may be beneficial.

中文翻译：

---

扁桃体炎患者分离的A组β溶血性链球菌种、emm和外毒素基因的检测

A 组 Beta 溶血性链球菌 (GAS) 是导致扁桃体咽炎的最关键的人类病原体。本研究的目的是确定 GAS 分离株并确定 emm 分型、可用疫苗的覆盖率以及超抗原基因谱的分布。从2017年10月至2018年5月期间入住Canakkale健康应用与研究医院的200名扁桃体咽炎患者的喉部培养物中分离出15株GAS分离株。分离株的鉴定采用常规方法和16S rRNA序列分析。通过聚合酶链反应对分离株进行 emm 分型和外毒素分析。在 200 名患者中检测到 7.5% 的 GAS。所有 GAS 分离株均被鉴定为化脓性链球菌。emm 分型可以在 13 株化脓链球菌中进行。emm89 (33.3%), 发现 emm44 (20%)、emm6 (13.3%)、emm84 (6.7%)、emm1 (6.7%) 和 emm18.1 (6.7%) 是六种 emm 类型。26价疫苗的化脓性链球菌菌株覆盖率为61.5%，30价疫苗为84.6%。最常见的外毒素是speB（86.7%），其次是speC（60%）、speF（33.3%）、ssa（26.7%）、speA（20%）、speM（20%）、speJ（13.3%）、speL (6.7%) 和 SPEI (6.7%)。由于确定了恰纳卡莱化脓性链球菌的 emm 类型，得出的结论是，土耳其应考虑 30 价疫苗的潜力，开发含有外毒素类型的疫苗可能是有益的。7%)，然后是 speC (60%)、speF (33.3%)、ssa (26.7%)、speA (20%)、speM (20%)、speJ (13.3%)、speL (6.7%) 和 speI (6.7%)。由于确定了恰纳卡莱化脓性链球菌的 emm 类型，得出的结论是，土耳其应考虑 30 价疫苗的潜力，开发含有外毒素类型的疫苗可能是有益的。7%)，然后是 speC (60%)、speF (33.3%)、ssa (26.7%)、speA (20%)、speM (20%)、speJ (13.3%)、speL (6.7%) 和 speI (6.7%)。由于确定了恰纳卡莱化脓性链球菌的 emm 类型，得出的结论是，土耳其应考虑 30 价疫苗的潜力，开发含有外毒素类型的疫苗可能是有益的。